Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lineage Cell Therapeutics (LCTX) Change in Receivables: 2010-2025

Historic Change in Receivables for Lineage Cell Therapeutics (LCTX) over the last 15 years, with Sep 2025 value amounting to -$130,000.

  • Lineage Cell Therapeutics' Change in Receivables fell 176.92% to -$130,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$278,000, marking a year-over-year decrease of 717.65%. This contributed to the annual value of -$106,000 for FY2024, which is 123.77% down from last year.
  • As of Q3 2025, Lineage Cell Therapeutics' Change in Receivables stood at -$130,000, which was down 402.33% from $43,000 recorded in Q2 2025.
  • Lineage Cell Therapeutics' Change in Receivables' 5-year high stood at $753,000 during Q4 2021, with a 5-year trough of -$50.3 million in Q1 2022.
  • Over the past 3 years, Lineage Cell Therapeutics' median Change in Receivables value was $43,000 (recorded in 2025), while the average stood at -$15,545.
  • Its Change in Receivables has fluctuated over the past 5 years, first slumped by 37,374.81% in 2022, then skyrocketed by 2,916.67% in 2024.
  • Lineage Cell Therapeutics' Change in Receivables (Quarterly) stood at $753,000 in 2021, then tumbled by 114.34% to -$108,000 in 2022, then surged by 382.41% to $305,000 in 2023, then dropped by 23.61% to $233,000 in 2024, then tumbled by 176.92% to -$130,000 in 2025.
  • Its Change in Receivables was -$130,000 in Q3 2025, compared to $43,000 in Q2 2025 and -$424,000 in Q1 2025.